WCG MedAvante-ProPhase

WCG MedAvante-ProPhase is the leading global provider of technology-enabled signal detection solutions in clinical trials of treatments for central nervous system (CNS) disorders with more than two decades of experience improving clinician-reported diagnostic and outcome measurements. MedAvante-ProPhase standardizes rating scale administration and scoring with the Virgil? Investigative Study Platform, a powerful approach to signal detection that puts the advantages of our experience in the hands of site raters as a tablet computer with unique context-sensitive electronic rating scale forms and study-specific clinical guidance, designed by clinicians for clinicians. We prepare and qualify clinical raters with effective, measurable rater training, and we assure ongoing data quality with Independent Review, over-read of assessment outcomes by expert central clinicians. Maximal protection against the risk of inconclusive results is delivered by MedAvante-ProPhase Independent Ratings, which in addition to standardizing scale administration and scoring avoids critical sources of perception bias that may block signal detection. Continuously trained and standardized remote Expert Clinicians are blind to protocol details and subject history, immune to the confounding impact of repeated contact with patients and free of pressure to enroll subjects. Independent Ratings have been used in more than 57 major trials completed to date. Supported by operations teams in the US, Germany, Russia and Japan, MedAvante-ProPhase delivers services for clinical trials in more than 40 countries worldwide. For more information, please visit www.medavante.com.

网站

https://www.medavante-prophase.com

WCG MedAvante-ProPhase的外部链接

所属行业

制药业

规模

201-500 人

总部

Hamilton，New Jersey

类型

私人持股

创立

2002

领域

Clinical Trials、Signal Detection、Risk Reduction、Rater Training、eSource Data (Virgil Investigative Study Platform)和Clinical Over-Read (Central Review)